Kornimate/medical-research-clean huggingface dataset:
effect of soy on cognition and hot flashes in men with prostate cancer undergoing testosterone suppression therapy

Conditions: Hot Flashes

Summary: this study will look at the effects of a soy supplement called revival on memory, quality of life, and hot flashes in men with prostate cancer who are being treated with testosterone suppression therapy. hypothesis: treating men who have prostate ca with daily revival will result in at least a 50% reduction in hot flashes compared to placebo.

this research study will look at the effects of a soy supplement called revival on memory, quality of life, and hot flashes in men with prostate cancer who are undergoing (adt) androgen deprivation therapy. participants will be given either placebo or revival. participants will be asked to take their supplement once/day for 14 weeks.blood will be drawn to check on liver, kidney, thyroid, cholesterol,and prostate health. urine will be collected to check on bone markers. patients will be asked to complete questionnaires to test memory, attention span, and vocabulary.possible benefits may include increase in memory, decrease in hot flashes, and a general increase in quality of life.

Eligibility criteria:
inclusion criteria: * men \> or =21 with prostate ca and hypogonadism for at least 3 months exclusion criteria: * on growth promoting agents * on appetite stimulating agents * on prednisone and others

Keywords: prostate cancer soy androgen deprivation quality of life isoflavones
optical coherence tomography angiography in subjects with retinal vascular disease

Conditions: Diabetic Retinopathy; Retinal Vein Occlusion; Hypertension,Essential; Retinal Vascular Disorder

Summary: this study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. this includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

the objective of this study is to perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. this includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment. subjects will be identified from healthy subjects (seen for screening eye exams) and diseased subjects undergoing standard-of-care treatment or screening at eye clinic locations. the study population will include subjects with retinal vascular disease including but not limited to diabetic retinopathy, hypertension, retinal vein/arterial occlusion, and macular degeneration. subjects who are enrolled will undergo non-invasive, minimal risk, fda approved diagnostic imaging procedures to identify vascular changes. the study methods will include retrospective review and collection of clinically approved imaging data that is obtained through standard-of-care methods for subjects who meet inclusion and exclusion criteria. subjects who are identified in this manner will be asked to participate in a prospective study by each clinical study site. the study end-points include the correlation of diagnostic imaging findings from optical coherence tomography (oct) based images with fundus photographs, clinical disease stage and visual acuity.

Eligibility criteria:
exclusion criteria: * both subjects with diseases and controls: * children (age\<18) * pregnant females * developmentally delayed subjects * subjects unable to provide informed consent * inability to cooperate with tests and study instructions * images with motion artifact or signal strength \< 7 * history of glaucoma * history of age-related macular degeneration * history of any visually significant eye disease * history of proliferative diabetic retinopathy * history of any inflammatory disease * history of heart disease * history of thyroid disease. * additional criteria for controls: * history of any type of diabetes mellitus * history of any type of hypertension
feasibility and safety and evaluation of the potential efficacy of autologous platelet-rich plasma in the treatment of vascular venous ulcers

Conditions: Chronic Ulcer

Summary: introduction: vascular ulcers are an important pathology in the daily medical practice in all the assistance levels, and they have big repercussion referring to individual, social and labour levels, supposing a big consumption of human and material resources.the cure with autologous platelet rich plasma (autologous prp) has demonstrated in different studies a decrease in the cicatrization time comparing to conventional methods in hospital levels, which becomes interesting contrasting its efficacy in primary care. aim:evaluate the practicability, security and potential of the autologous prp in the treatment of vascular ulcers, comparing to the conventional treatment ( cure with humid environment), in primary care patients with chronic venous insufficiency in c-6 degree (ceap classification). design:a pilot study will be executed, which will consist in a randomized clinical test, multicentred, in parallel groups and opened. 40 patients suffering of venous vascular ulcers will be studied, who will be between the age of 40-80 years old, and who will be attached to five health centers. variables for the identification, following, result and patient profile have been defined. emphasize the variables of "ulcer area decreasing", "civiq index", "% one cure per week" .


Eligibility criteria:
inclusion criteria: * patients resident in barakaldo, who are seen in treatment rooms at the zaballa outpatient clinic or one of the following health centres: zaballa, la paz, urban, or san vicente, in the ezkerraldea-enkarterri health region of the basque health service - osakidetza. * men or women of 40 to100 years of age * patients with stage c6 chronic venous insufficiency according to the ceap classification * patients with vascular ulcers which have not responded to conventional treatment in 2 to 6 months * patients who present an analytical before entering the study with a normal range of number of platelets, red blood cells and hematocrit * an ulcer of 3-5 cm in diameter * an abi of greater than or equal to 0.8 or less than or equal to 1.5. * independent patients or with sufficient family support * patients have given written informed consent exclusion criteria: * patients with chronic treatment with immunosuppressive or retroviral drugs * coagulopathies * patients with chronic infectious diseases * patients under radiotherapy or chemotherapy * patients with a history of neoplasia * patients with more than two active ulcers * pregnant women * patients with active cellulitis or fever * an abi of less than 0.8 or more than 1.5.

Keywords: prp chronic vascular ulcer primary care
effect of honey for cin ii

Conditions: Cervical Intraepithelial Neoplasia-II; High Risk Human Papillomavirus

Summary: the following hypothesis is tested: medical grade honey in cin ii causes a higher clearance of the hr-hpv virus and an increase in the normalization of cin ii lesions compared to expectant management.

in this pilot study, we will include 60 patients with newly diagnosed cin ii. patients will be counseled according to standard guidelines between a lletz, imiquimod or expectant management. patients choosing for expectant management will be asked to participate in the study and will be treated with medical grade honey. patients choosing for expectant management but not participating in the study and thus not using medicinal honey will be asked for the control arm. follow-up assessment takes place in accordance with the national guideline (first check-up is after 6 months). in addition, swabs for vaginal microbiota analysis will be taken at 0 and 6 months. immunohistochemical stainings for the local immune infiltrate will be performed on biopsies taken during regular colposcopy at t=0. this exploratory study aims to investigate if there is a potential effect of honey and provides insight into its mechanisms of action.

Eligibility criteria:
inclusion criteria: * women 18-40 years * primary cin ii confirmed histologically in the biopsy on colposcopic examination * sufficient mastery of the dutch language exclusion criteria: * simultaneous abnormality in columnar epithelial cells (ais). * hr-hpv negative cytology * immunosuppressant use/autoimmune disease (hiv, cvid) * history of cervical carcinoma or previous treatment for cin (lletz or imiquimod) * pregnancy or the intention to become pregnant during the study period * legal incompetence * known allergies to honey

Keywords: honey cinii
effect of palifermin on skin tumors in patients undergoing bone marrow transplantation

Conditions: Skin Rash

Summary: we are approaching you to participate in this study because you are taking palifermin and the purpose of this study is to describe the effect of palifermin on skin growth found on the body. palifermin is a new synthetic growth factor (encourages skin cells to grow) specifically designed to protect the areas of the body (mouth and upper digestive tract) that are damaged by chemotherapy. the cells in these areas are rapidly dividing cells and so are killed by chemotherapeutic drugs. palifermin is a drug that stimulates new cells in these areas to grow and therefore protects patients from some serious side effects of chemotherapy. these include mucositis or inflammation of the lining of the mouth and other organs resulting in difficulty swallowing, speaking and extreme pain in the mouth and upper digestive tract. skin cells are also known to respond to these types of growth factors like palifermin, but unfortunately no studies have been done that look specifically at the effect of this drug on pre-existing skin lesions or the development of new skin lesions. we will be asking you if you have noticed any change in moles or other skin lesions that you have, and if you have noticed any new lesions. we will also be doing a full physical examination of the skin at regular intervals during the study to document the appearance of any new lesions or change in pre-existing ones.


Eligibility criteria:
inclusion criteria: receiving bone marrow transplant - exclusion criteria: not receiving other growth factors -
anlotinib combined with tace in hepatocellular carcinoma patients at high risk of post surgery recurrence

Conditions: Hepatocellular Carcinoma; TACE; Anlotinib

Summary: a single-arm, open-label clinical trial to assess the effects and safety of anlotinib hydrochloride combined with transcatheter arterial chemoembolization (tace) in hepatocellular carcinoma(hcc) patients at high risk of post surgery recurrence.

hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. recurrence of hcc is still a great challenge and threat to the patients after resection surgery. anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (vegfr), fibroblast growth factor receptor (fgfr), platelet-derived growth factor receptors (pdgfr), and c-kit. hcc patients who meet the eligibility criteria of this clinical trial will adopt postoperative tace combined with anlotinib hydrochloride. at day4 of tace,anlotinib 12mg qd po d1-14, 21 days per cycle until disease progresses or intolerant. primary efficacy endpoint: disease free survival (dfs);secondary efficacy endpoints: 1-year dfs rate and time to recurrence (ttr)(according to recist version 1.1).safety will be evaluated by incidence, severity and outcomes of aes and categorized by severity in accordance with the nci ctc ae version 4.0.

Eligibility criteria:
inclusion criteria: * patients participate in the study voluntarily and sign informed consent with good compliance. * after hepatectomy, satisfy any of the following recurrence factors was assessed:≥5 cm and \< 10 cm of tumor diameter; tumor number≥3; tumor microvascular invasion grade m1; portal vein carcinoma thrombus resection(ⅰ、ⅱ). * histological or cytological confirmation of hepatocellular carcinoma, or at least two imaging tests with hepatocellular carcinoma characteristics, or one imaging test with hepatocellular carcinoma characteristics and afp \> 400μg/l. * tace treatment (ctace only) was completed within 1-2 months after hepatectomy. * ≥ 18 and ≤ 75 years of age. * ecog performance status of 0-1. * liver function child-pugh class a or b (≤7 points). * except for hepatectomy, no previous tumor-related treatment was received, and the remaining liver was assessed to have good liver function. exclusion criteria: * patients who have had or are currently complicated with other malignant tumors,or recurrent hepatocellular carcinoma (\>10 mm)in baseline data or in tace. * patients with absolute contraindications to tace. * patients with hcv infection. * urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed. * pregnant or lactating women. * patients with mental illness.
galvanic vestibular stimulation as a novel treatment for seasickness

Conditions: Motion Sickness; Seasickness; Habituation; Vestibular Time Constant

Summary: subjects with severe seasickness, who failed to habituate to sea conditions after at least six month of active sailing, were enrolled to the single-blind randomized control study. the intervention group was treated with rotatory chair stimulation at sinusoidal harmonic acceleration protocol coupled with galvanic vestibular stimulation to the mastoid processes. this unique procedure was hypothesized to promote habituation to seasickness. the control group underwent a sham procedure. all study participants filled out seasickness questionnaires at set time points following the intervention and underwent repeated step testing to determine their vestibular time constant. the number of anti-motion sickness clinic visits and scopolamine prescriptions was also recorded in the three months period following the intervention.


Eligibility criteria:
inclusion criteria: * maximum score of 7 on the wiker seasickness questionnaire in moderate sea conditions, with wave height of 0 - 1.5 m * all had been sailing regularly for at least six months before enrolling in the study exclusion criteria: * history of hearing loss * otoscopic findings of ear pathology * an implanted electrode * a finding of vestibulopathy on otoneurologic examination * withdrawal by any subject of his informed consent.

Keywords: motion sickness seasickness galvanic vestibular stimulation rotatory chair vestibular time constant
peer support program in chronic kidney patient

Conditions: Peer Review; Hemodialysis Complication; Nurse's Role; Health-Related Behavior

Summary: the main advantage of patient-to-patient peer counseling is that it benefits both the client and the peer mentors as real and authentic experiences are shared. since both individuals go through similar experiences, they can share common feelings. although there are studies in the literature showing the effectiveness of peer support groups in different patient groups, studies on chronic kidney disease patients are limited. there are no studies on the effects of these programs on caregivers. this study will be conducted to examine the effects of peer support program applied to chronic kidney patients on patient outcomes and caregivers.

this study was planned to be conducted with a randomized controlled experimental design to examine the effect of the peer support program applied to chronic kidney patients on patient outcomes and caregivers. patients diagnosed with chronic kidney disease and receiving haemodialysis (hd) as a renal replacement method constitute the population of the study. in the a priori power analysis performed to calculate the number of subjects, the effect size was taken as 1.3 (d) based on reference studies. accordingly, it was found that 34 subjects should be included in the calculation for the independent two-sample t-test according to 0.95 power and 0.05 alpha. the sample of the study will consist of 25 intervention and 25 control ckds who fulfil the inclusion criteria, taking into account the dropout status.

Eligibility criteria:
inclusion and exclusion criteria for peer mentor inclusion criteria; * speaking turkish * to be literate * ckd receiving haemodialysis * volunteering * 18 years of age or older * being open to communication and co-operation * not having any psychiatric disorder for patient inclusion criteria; * speaking turkish * to be literate * ckd receiving haemodialysis * volunteering * 18 years of age or older * not having any psychiatric disorder exclusion criteria for all participants * being under 18 years of age * speaking a language other than turkish * not being able to use a telephone losses to follow-up * experiencing incompatibility with the second peer mentor or client with whom they are paired for peer mentor and peer client * death during the period of intervention or follow-up * withdrawal of patient consent * clinical problems or difficulties attending appointments that hinder follow-up

Keywords: peer sport nursing hemodialysis
effects of pelvic girdle stabililty with use of therapeutic taping in down syndrome

Conditions: Down Syndrome

Summary: a interventional study on 16 down syndrome pateints and check effects o therapeutic taping on pelvic girdle stability on 8 weeks sessions

study group a will undergo pelvic girdle stablilty traing along with therapeutic taping and group b will receive pelvic girdle satbility traing of 8 weeks and chcek the effects by trunk control assessement tool,gross motor functional scale .this study type is conviennet sampling techniques and check effetcts by exercising

Eligibility criteria:
inclusion criteria: * functional hearing and vision * ability to understand commands. exclusion criteria: * children with severe mental retardation * history of trauma and surgery'

Keywords: down syndrome therapeutic taping trunk control pelvic girdle
evaluation of bilateral tecnis multifocal versus restor 3d intraocular lenses

Conditions: Cataract

Summary: the purpose of this study is to compare the visual outcomes with bilateral implantation of tecnis mf and restor intraocular lenses (iols) 6 months post cataract surgery.


Eligibility criteria:
inclusion criteria: * age 18 or greater * bilateral cataracts for which phacoemulsification extraction and posterior iol implantation has been planned for both eyes * visual potential of 20/30 or better in each eye after cataract removal and iol implantation * preoperative best-corrected distance visual acuity (bsdva) worse than 20/40 snellen. if there is a glare component, glare testing which reduces the visual acuity to less than 20/40 * naturally dilated pupil size (in dim light) \> 3.5 mm (with no dilation medications) for both eyes * preoperative corneal astigmatism of 1.0 d or less * clear intraocular media other than cataract * availability, willingness, and sufficient cognitive awareness to comply with examination procedures exclusion criteria: * use of systemic or ocular medications that may affect vision * acute or chronic disease or illness that would increase risk or confound study results (e.g. diabetes mellitus, immunocompromised, etc.) * subjects with diabetes mellitus * uncontrolled systemic or ocular disease * history of ocular trauma or prior ocular surgery * amblyopia or strabismus * known pathology that may affect visual acuity; particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) * diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal disorders) that are predicted to cause future acuity losses to a level of 20/30 or worse * subjects who may be expected to require retinal laser treatment or other surgical intervention * capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome) * pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 4.0 mm under mesopic/scotopic conditions) * contact lens usage within 6 months for polymethyl methacrylate (pmma) contacts lenses, 1 month for gas permeable lenses or 1 week for extended-wear and daily-wear soft contact lenses * requiring an intraocular lens \ 26.0 diopters

Keywords: compare the visual outcomes with bilateral implantation of tecnis mf and restor iols 6 months post cataract surgery.
feasibility study of deep learning-based mdixon quant for quantitative assessment of chemotherapy-induced fatty liver

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: the purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment. the main questions it aims to answer are:how does the liver fat fraction change before and after chemotherapy? in this study, patients undergoing mdixon quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.

regarding the extraction of liver fat fraction, the traditional axial roi method involves selecting several regions of interest (rois) at the largest cross-sectional level or across multiple continuous sections, and taking the average value as the whole-liver fat fraction. this method is complex, time-consuming, and cannot obtain the whole-liver fat fraction. in this study, a threshold extraction method is used to obtain the whole-liver fat fraction, enabling a 2d-to-3d conversion, which is more time-efficient and labor-saving, and provides a more accurate measurement.

Eligibility criteria:
inclusion criteria: 1. ct/b ultrasound showed no fatty liver 2. no mri contraindications, including pacemaker, stent, metal implant, or claustrophobia 3. received neoadjuvant/adjuvant chemotherapy exclusion criteria: 1. missing follow-up information 2. liver lesions (metastases, hemangioma, etc.) 3. poor image quality